Literature DB >> 12145326

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects.

Xiaorong Zhu1, An Zhou, Arunangsu Dey, Christina Norrbom, Raymond Carroll, Chunling Zhang, Virginie Laurent, Iris Lindberg, Randi Ugleholdt, Jens J Holst, Donald F Steiner.   

Abstract

The subtilisin-like proprotein convertases PC1/3 (SPC3) and PC2 (SPC2) are believed to be the major endoproteolytic processing enzymes of the regulated secretory pathway. They are expressed together or separately in neuroendocrine cells throughout the brain and dispersed endocrine system in both vertebrates and invertebrates. Disruption of the gene-encoding mouse PC1/3 has now been accomplished and results in a syndrome of severe postnatal growth impairment and multiple defects in processing many hormone precursors, including hypothalamic growth hormone-releasing hormone (GHRH), pituitary proopiomelanocortin to adrenocorticotropic hormone, islet proinsulin to insulin and intestinal proglucagon to glucagon-like peptide-1 and -2. Mice lacking PC1/3 are normal at birth, but fail to grow normally and are about 60% of normal size at 10 weeks. They lack mature GHRH, have low pituitary growth hormone (GH) and hepatic insulin-like growth factor-1 mRNA levels and resemble phenotypically the "little" mouse (Gaylinn, B. D., Dealmeida, V. I., Lyons, C. E., Jr., Wu, K. C., Mayo, K. E. & Thorner, M. O. (1999) Endocrinology 140, 5066-5074) that has a mutant GHRH receptor. Despite a severe defect in pituitary proopiomelanocortin processing to mature adrenocorticotropic hormone, blood corticosterone levels are essentially normal. There is marked hyperproinsulinemia but without impairment of glucose tolerance. In contrast, PC2-null mice lack mature glucagon and are chronically hypoglycemic (Furuta, M., Yano, H., Zhou, A., Rouille, Y., Holst, J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H. & Steiner, D. (1997) Proc. Natl. Acad. Sci. USA 94, 6646-6651). The PC1/3-null mice differ from a human subject reported with compound heterozygosity for defects in this gene, who was of normal stature but markedly obese from early life. The PC1/3-null mice are not obese. The basis for these phenotypic differences is an interesting topic for further study. These findings prove the importance of PC1/3 as a key neuroendocrine convertase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145326      PMCID: PMC124907          DOI: 10.1073/pnas.162352599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Posttranslational processing of progrowth hormone-releasing hormone.

Authors:  E A Nillni; R Steinmetz; O H Pescovitz
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

2.  Prohormone convertase PC4 processes the precursor of PACAP in the testis.

Authors:  M Li; M Mbikay; K Nakayama; A Miyata; A Arimura
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

3.  Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice.

Authors:  M Furuta; A Zhou; G Webb; R Carroll; M Ravazzola; L Orci; D F Steiner
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

4.  Structure, measurement, and secretion of human glucagon-like peptide-2.

Authors:  B Hartmann; A H Johnsen; C Orskov; K Adelhorst; L Thim; J J Holst
Journal:  Peptides       Date:  2000-01       Impact factor: 3.750

5.  Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet.

Authors:  M K Gutniak; H Larsson; S J Heiber; O T Juneskans; J J Holst; B Ahrén
Journal:  Diabetes Care       Date:  1996-08       Impact factor: 19.112

6.  SPC4/PACE4 regulates a TGFbeta signaling network during axis formation.

Authors:  D B Constam; E J Robertson
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

7.  The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH.

Authors:  B D Gaylinn; V I Dealmeida; C E Lyons; K C Wu; K E Mayo; M O Thorner
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

Review 8.  Glucagon-like peptide 2.

Authors:  D J Drucker
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

9.  Defective prodynorphin processing in mice lacking prohormone convertase PC2.

Authors:  Y Berman; N Mzhavia; A Polonskaia; M Furuta; D F Steiner; J E Pintar; L A Devi
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

10.  Stimulation of growth in the little mouse.

Authors:  W H Beamer; E M Eicher
Journal:  J Endocrinol       Date:  1976-10       Impact factor: 4.286

View more
  118 in total

1.  Deep sequencing reveals 50 novel genes for recessive cognitive disorders.

Authors:  Hossein Najmabadi; Hao Hu; Masoud Garshasbi; Tomasz Zemojtel; Seyedeh Sedigheh Abedini; Wei Chen; Masoumeh Hosseini; Farkhondeh Behjati; Stefan Haas; Payman Jamali; Agnes Zecha; Marzieh Mohseni; Lucia Püttmann; Leyla Nouri Vahid; Corinna Jensen; Lia Abbasi Moheb; Melanie Bienek; Farzaneh Larti; Ines Mueller; Robert Weissmann; Hossein Darvish; Klaus Wrogemann; Valeh Hadavi; Bettina Lipkowitz; Sahar Esmaeeli-Nieh; Dagmar Wieczorek; Roxana Kariminejad; Saghar Ghasemi Firouzabadi; Monika Cohen; Zohreh Fattahi; Imma Rost; Faezeh Mojahedi; Christoph Hertzberg; Atefeh Dehghan; Anna Rajab; Mohammad Javad Soltani Banavandi; Julia Hoffer; Masoumeh Falah; Luciana Musante; Vera Kalscheuer; Reinhard Ullmann; Andreas Walter Kuss; Andreas Tzschach; Kimia Kahrizi; H Hilger Ropers
Journal:  Nature       Date:  2011-09-21       Impact factor: 49.962

Review 2.  Furin at the cutting edge: from protein traffic to embryogenesis and disease.

Authors:  Gary Thomas
Journal:  Nat Rev Mol Cell Biol       Date:  2002-10       Impact factor: 94.444

3.  Allelic clustering and ancestry-dependent frequencies of rs6232, rs6234, and rs6235 PCSK1 SNPs in a Northern Ontario population sample.

Authors:  Francine Sirois; Nadine Kaefer; Krista A Currie; Michel Chrétien; Kabwe K Nkongolo; Majambu Mbikay
Journal:  J Community Genet       Date:  2012-02-04

Review 4.  T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus.

Authors:  Cedrick D Dotson; Stephan Vigues; Nanette I Steinle; Steven D Munger
Journal:  Curr Opin Investig Drugs       Date:  2010-04

5.  Endocrinomic profile of neurointermediate lobe pituitary prohormone processing in PC1/3- and PC2-Null mice using SELDI-TOF mass spectrometry.

Authors:  Atira Hardiman; Theodore C Friedman; William C Grunwald; Machi Furuta; Ziaorong Zhu; Donald F Steiner; David R Cool
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

6.  Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation.

Authors:  Patricia M Vuguin; Mamdouh H Kedees; Lingguang Cui; Yelena Guz; Richard W Gelling; Morris Nejathaim; Maureen J Charron; Gladys Teitelman
Journal:  Endocrinology       Date:  2006-04-20       Impact factor: 4.736

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Core formation and the acquisition of fusion competence are linked during secretory granule maturation in Tetrahymena.

Authors:  Grant R Bowman; Nels C Elde; Garry Morgan; Mark Winey; Aaron P Turkewitz
Journal:  Traffic       Date:  2005-04       Impact factor: 6.215

9.  Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.

Authors:  H Wang; M Iezzi; S Theander; P A Antinozzi; B R Gauthier; P A Halban; C B Wollheim
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

10.  Differential processing of neuropeptide proprotein in human breast adenocarcinoma.

Authors:  J H Zhang; D Zhou; J You; B S Tang; P Y Li; S S Tang
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.